Conversation with The Cancer Letter NCI’s Korde: Follow-up needed to validate PFS with mature OS results for Tecentriq October 26, 2018Vol.44 No.40By Matthew Bin Han Ong
Long-awaited trial of checkpoint inhibitor in breast cancerproduces 2-month PFS gain; no final OS advantage seen—yet October 26, 2018Vol.44 No.40By Matthew Bin Han Ong
Caligiuri, Califano, Gottlieb among new members of National Academy of Medicine October 19, 2018Vol.44 No.39
Here are the strings attached to the NIH funding increase: House and Senate report language October 19, 2018Vol.44 No.39By Paul Goldberg
So, you’d like a cancer center designation… Sharpless offers advice on what makes a center in the era of“outreach and engagement” October 19, 2018Vol.44 No.39By Paul Goldberg
Conversation with The Cancer LetterFree Sharpless: “I am now looking at the entire portfolio—focusing on areas where NCI is an essential player” October 19, 2018Vol.44 No.39By Paul Goldberg
Trials & Tribulations Biomarker linked to increased survival rates among certain brain tumor patients October 12, 2018Vol.44 No.38By Arnab Chakravarti
Conversation with The Cancer Letter WHO’s Ilbawi: St. Jude partnership can resolve inequality, capacity issues in childhood cancer October 12, 2018Vol.44 No.38By Matthew Bin Han Ong
Conversation with The Cancer Letter St. Jude’s Downing: WHO effort can raise cure rates up to 60% for children with cancer October 12, 2018Vol.44 No.38By Matthew Bin Han Ong
